GreenRoc Accelerates their World Class Project to Production as Early as 2028. Watch the full video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAllergy Thera. Share News (AGY)

Share Price Information for Allergy Thera. (AGY)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 5.10
Bid: 5.00
Ask: 5.20
Change: -0.10 (-1.92%)
Spread: 0.20 (4.00%)
Open: 5.15
High: 5.16
Low: 5.10
Prev. Close: 5.20
AGY Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON MARKET MIDDAY: Covid concerns in China drag stocks lower

Thu, 29th Dec 2022 12:14

(Alliance News) - Stock prices in London at midday continued to be weighed down by the worrying surge in Covid-19 cases as China swiftly re-opens from three years of strict lockdown measures.

"The good news with China's re-opening is that it should boost global growth. The bad news with China's reopening is that it will not only boost global growth, but also energy and commodity prices - hence inflation, the interest rate hikes from central banks and potentially the global Covid cases – which could then give birth to a new, and a dangerous Covid variant, which would, in return, bring the restrictive Covid measures back on the table, and hammer growth," said Ipek Ozkardeskaya at Swissquote Bank.

The FTSE 100 index was down 9.35 points, or 0.1%, at 7,487.84. The FTSE 250 was down 61.52 points, or 0.3% at 18,823.98, and the AIM All-Share was down 1.11 points, or 0.1%, at 831.17.

The Cboe UK 100 was down 0.2% at 748.97, the Cboe UK 250 down 0.4% at 16,295.30, and the Cboe Small Companies down 0.2% at 13,104.65.

Hospitals across China have been overwhelmed by an explosion of Covid cases following Beijing's decision to lift strict rules that had largely kept the virus at bay. 

On Monday, the country said it would bring an end to mandatory quarantine on arrival – prompting many jubilant Chinese citizens to make plans to travel abroad. In response, the US and a number of other countries announced they would require negative Covid tests for all travellers from mainland China.

Stocks in New York were called higher after Wednesday's steep sell-off. The Dow Jones Industrial Average was called up 0.2%, the S&P 500 index up 0.5%, and the Nasdaq Composite up 0.7% on Thursday. The indices closed down 1.1%, 1.2% and 1.4%, respectively, on Wednesday.

interactive investor's Victoria Scholar said continued worries about the performance of 'big tech', fears of a recession, rising interest rates, and China's complex Covid situation were weighing on Wall Street.

In London, Antofagasta fell 1.0%, after the miner reported that access to its Los Pelambres operation in Chile is being blocked by a group of people, affecting the transport of critical supplies and personnel to the mine site.

Antofagasta explained that the group is requesting compensation to clear access but added that, to date, there has been no material impact on production.

"The authorities are working to clear the blockade, and the company is engaging with them and representatives of the local communities to jointly resolve the situation," Antofagasta said.

Allergy Therapeutics plunged 52% after it said its shares will be suspended from trading next week, due to delays in completing the audit of its annual results.

Back in September, Allergy Therapeutics announced its unaudited preliminary results for the financial year that ended June 30. It sunk to a pretax loss of GBP12.7 million from a profit of GBP3.7 million the year prior. Revenue dropped to GBP72.8 million from GBP84.3 million.

"It is not aware of any material change that will be required to be made to the results, and it is actively working to finalise the audit and publication of its annual report and accounts," Allergy Therapeutics said.

Kazera Global dropped 22%. It also said its results will not be published before the end of the year, due to delays at its wholly-owned subsidiary African Tantalum.

The diamond and rare earths explorer now expects to release its results for the financial year that ended June 30 during February. As a result, its shares will be suspended from trading on AIM in London from Tuesday next week, the first trading day of 2023.

Tekcapital jumped 8.2%. It said investee Innovative Eyewear licensed outdoor brand Eddie Bauer for its smart eyewear collection through an agreement with Authentic Brands.

The company described the contract as a "multi-year, global licensing agreement", without providing financial details. The Eddie Bauer smart eyewear collection is expected to launch in 2023.

Index operator FTSE Russell revealed on Wednesday that Johnson Matthey will return to the FTSE 100 next week as part of index changes stemming from the acquisition of home repairs company Homeserve.

Johnson Matthey had been dumped from the FTSE 100 just over a year ago following an index review. Shares in the speciality chemicals firm were down 1.0% at midday on Thursday.

Early Thursday afternoon in Europe, the CAC 40 index in Paris was up 0.1%, while the DAX 40 in Frankfurt was up 0.2%.

The pound was quoted at USD1.2026 at midday on Thursday in London, down a touch compared to USD1.2029 at the close on Wednesday.

The euro stood at USD1.0633, higher against USD1.0617. Against the yen, the dollar was trading at JPY133.75, lower compared to JPY134.23.

Brent oil was quoted at USD83.00 a barrel at midday in London on Thursday, up from USD82.87 late Wednesday. Gold was quoted at USD1,806.05 an ounce, higher against USD1,801.04.

Still to come on Thursday's economic calendar, there are US weekly unemployment insurance claims at 1330 GMT.

By Heather Rydings, Alliance News senior economics reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2022 Alliance News Ltd. All Rights Reserved.

More News
23 Oct 2018 16:11

BlackRock Lowers Allergy Therapeutics Stake Below Threshold (ALLISS)

LONDON (Alliance News) - Allergy Therapeutics PLC said Tuesday that BlackRock Inc lowered its stake in the company to below the 5% threshold.Prior to the deal, BlackRock held a 5.1% in the

Read more
26 Sep 2018 12:42

Allergy Therapeutics Interim Loss Widens But Germany Pushes Revenue Up

LONDON (Alliance News) - Allergy Therapeutics PLC on Wednesday said its loss widened in the first half of 2018, but revenue rose on strong performance in Germany and a strengthening of the company

Read more
19 Jul 2018 11:08

Allergy Therapeutics To Raise GBP11 Million Via Share Issue (ALLISS)

LONDON (Alliance News) - Allergy Therapeutics PLC said Thursday that it will raise up to GBP10.6 million via placing and subscription.The pharmaceutical company focused on allergy vaccines

Read more
29 May 2018 11:19

Allergy Therapeutics Reveals Good Results From Dust Mite Allergy Tests

LONDON (Alliance News) - Biotechnology firm Allergy Therapeutics PLC said it will present positive new data on its dust mite allergy treatment at a congress in Germany on Tuesday.Allergy is

Read more
21 May 2018 11:49

Allergy Therapeutics Reports Positive Results From Grass Pollen Study

LONDON (Alliance News) - Allergy Therapeutics PLC said Monday it saw positive results from its grass pollen allergy treatment phase II dose ranging study as it prepares to commence in phase III it

Read more
14 May 2018 12:24

Allergy Therapeutics Gets Positive Indications In Latest MCT Study

LONDON (Alliance News) - Biotechnology firm Allergy Therapeutics PLC on Monday said it has received positive new data in a study investigating its microcrystalline tyrosine-based results, it said,

Read more
16 Mar 2018 17:30

DIRECTOR DEALINGS: Allergy Therapeutics Non-Executive Lifts Stake

LONDON (Alliance News) - Pharmaceutical company Allergy Therapeutics PLC said Friday Non-Executive Director Tunde Otulana acquired shares on Thursday.Otulana acquired a

Read more
7 Mar 2018 13:42

Allergy Therapeutics Profit Falls On Costs As Pivotal Year Looms

LONDON (Alliance News) - Allergy Therapeutics PLC said Wednesday half year profit fell due to higher research and development costs, as the company prepares for 2018 clinical

Read more
14 Feb 2017 14:46

Allergy Therapeutics gets trial go-ahead in Spain

(ShareCast News) - Specialty pharmaceutical company Allergy Therapeutics announced on Tuesday that its Phase I clinical study investigating the safety and tolerability of Acarovac MPL received 'Clinical Trial Application' approval in Spain. The AIM-traded firm said it now expected the formulation to

Read more
14 Feb 2017 08:49

Allergy Therapeutics' House-Dust Mite Allergy Vaccine Trial Approved

Read more
2 Nov 2016 09:41

New broad patent strengthens Allergy Therapeutics portfolio

(ShareCast News) - Vaccine-focused pharmaceutical company Allergy Therapeutics announced on Wednesday that the European Patent Office has granted a broad technology patent relating to the its unique microcrystalline tyrosine depot adjuvant manufacturing process. The AIM-traded firm said the patent c

Read more
2 Nov 2016 09:29

Allergy Therapeutics Granted EU Patent For Microcrystalline Tyrosine

Read more
10 Oct 2016 11:59

Allergy Therapeutics examines potential of adjuvant portfolio

(ShareCast News) - Allergy Therapeutics will look into potential wider applications for its adjuvant technology after recent clinical research produced encouraging indications about both allergy vaccination and infectious disease applications. Microcrystalline tyrosine (MCT), an aluminium-free depot

Read more
29 Sep 2016 11:55

DIRECTOR DEALINGS: Allergy Therapeutics Chairman Lifts Stake

Read more
28 Sep 2016 10:41

DIRECTOR DEALINGS: Allergy Therapeutics Finance Boss Buys First Shares

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.